Status:
COMPLETED
Effect of Stopping Risedronate After Long Term Treatment on Bone Turnover
Lead Sponsor:
Warner Chilcott
Conditions:
Postmenopausal Women With Osteoporosis
Eligibility:
FEMALE
Up to 85 years
Phase:
PHASE3
Brief Summary
The effects of stopping long-term (7 years) and short term (2 years) risedronate therapy on BMD (bone mineral density) and BTMs (bone turnover markers) will be summarized.
Eligibility Criteria
Inclusion
- Post-menopausal women who sequentially completed studies RVE009093, RVE1996077, RVE1998080
Exclusion
- Less than 60% compliant between drug start and month 21
- Using bisphosphonates, glucocorticoids, anabolic steroids, vitamin D supplements, calcitrol, estrogen or estrogen-related drugs, progestogen, depot injection \>10,000 IU vitamin D, investigational drug
Key Trial Info
Start Date :
October 1 2001
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2003
Estimated Enrollment :
61 Patients enrolled
Trial Details
Trial ID
NCT01249261
Start Date
October 1 2001
End Date
May 1 2003
Last Update
November 2 2011
Active Locations (13)
Enter a location and click search to find clinical trials sorted by distance.
1
Investigational Site
Concord, New South Wales, Australia, 2139
2
Investigational Site
Parkville, Victoria, Australia, 3052
3
Investigational Site
De Pintelaan 185, Gent, Belgium, B-9000
4
Investigational Site
Hvidovre, Denmark, Denmark, DK-2650